Lv41
440 积分 2023-10-13 加入
Inactive Parp2 causes Tp53-dependent lethal anemia by blocking replication-associated nick ligation in erythroblasts
1小时前
求助中
Maintenance therapy for newly and recurrent epithelial ovarian cancer: current therapies and future perspectives
10天前
已完结
The recent advance and prospect of poly(ADP‐ribose) polymerase inhibitors for the treatment of cancer
16天前
已完结
PARP inhibitor resistant BRCA-mutated advanced breast cancer: current landscape and emerging treatments
16天前
已完结
The complex universe of inactive PARP1
16天前
已完结
A therapeutic algorithm guiding subsequent therapy selection after CDK4/6 inhibitors’ failure: a review of current and investigational treatment for HR+/Her2- breast cancer
16天前
已完结
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations
1个月前
已完结
Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies
1个月前
已完结
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial
1个月前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
1个月前
已完结
皖公网安备34019202002308
